Compare GE Aerospace (GE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs TransMedics Group Inc — how do they compare? GE Aerospace trades at $343 (market cap $375.97B), while TransMedics Group Inc trades at $76.77 (market cap $2.61B). The key difference: GE Aerospace is far larger — about 144× TransMedics Group Inc's market cap, and GE Aerospace pays a 0.52% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| GE | TMDX | |
|---|---|---|
Market Cap | $375.97B | $2.61B |
Sector | Industrials | Technology |
52-Week High | $378.68 | $150.42 |
52-Week Low | $259.00 | $61.99 |
Enterprise Value | $385.26B | $3.01B |
Dividend Yield | 0.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.
Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.
TransMedics (TMDX) trades at $77.46, up 3.85% on the day, with a bullish technical signal and strong analyst support. The company reported robust profitability with a 27.04% net margin and 45.22% ROE, though recent Q1 2026 earnings missed expectations. Strategic expansion into Europe via the PAD Aviation investment aims to strengthen its organ transplant logistics network, a key competitive advantage. The stock's valuation metrics include a P/E of 17.25 and P/S of 4.7.
The outlook remains positive with a $108.71 consensus price target (40% upside), supported by 9 buy ratings. Key opportunities include market share gains and European expansion, while risks involve margin pressure from investments and competitive threats. Execution on growth initiatives amid decelerating revenue growth will be critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
